Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation

B. Wake; C. Hyde; S. Bryan; P. M. Barton; F. Song; A. Fry-Smith; C. Davenport

doi:10.3310/hta6030

Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation

B. Wake, C. Hyde, S. Bryan, P. M. Barton, F. Song, A. Fry-Smith, C. Davenport

Research output: Contribution to journal › Article

22 Citations (Scopus)

Original language	English
Pages (from-to)	1-85
Number of pages	85
Journal	Health Technology Assessment
Volume	6
Issue number	3
DOIs	https://doi.org/10.3310/hta6030
Publication status	Published - 2002

Access to Document

10.3310/hta6030

Cite this

@article{bb32eaaa90484b25b80c97e77bcf4fd7,

title = "Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation",

author = "B. Wake and C. Hyde and S. Bryan and Barton, {P. M.} and F. Song and A. Fry-Smith and C. Davenport",

year = "2002",

doi = "10.3310/hta6030",

language = "English",

volume = "6",

pages = "1--85",

journal = "Health Technology Assessment",

issn = "1366-5278",

publisher = "National Co-ordinating Centre for HTA",

number = "3",

}

TY - JOUR

T1 - Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation

AU - Wake, B.

AU - Hyde, C.

AU - Bryan, S.

AU - Barton, P. M.

AU - Song, F.

AU - Fry-Smith, A.

AU - Davenport, C.

PY - 2002

Y1 - 2002

U2 - 10.3310/hta6030

DO - 10.3310/hta6030

M3 - Article

VL - 6

SP - 1

EP - 85

JO - Health Technology Assessment

JF - Health Technology Assessment

SN - 1366-5278

IS - 3

ER -